Compare Marathon Petroleum Corp (MPC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Viatris Inc — how do they compare? Marathon Petroleum Corp trades at $455.03 (market cap $130.12B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Marathon Petroleum Corp is far larger — about 6.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Viatris Inc for 57 Days on average.
| MPC | VTRS | |
|---|---|---|
Market Cap | $130.12B | $20.03B |
Volume | 2,749,647 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $463.34 | $18.27 |
52-Week Low | $162.63 | $9.74 |
Typical Hold Time | 54 Days | 57 Days |
Enterprise Value | $156.64B | $32.15B |
Dividend Yield | 0.86% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $463.34, up 4.77% with strong bullish momentum. The stock shows robust technical strength with consistent earnings beats and favorable valuation metrics including P/E of 16.07 and P/S of 0.9. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions create uncertainty. The company maintains solid profitability with 5.57% net margin and exceptional 47.9% ROE.
MPC presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include regulatory uncertainty and volatile energy markets. With 75.76% analyst buy ratings and $420.30 consensus target, the stock offers growth potential despite trading above target. Investors should weigh strong cash flow generation against exposure to energy policy changes and margin compression risks.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
